On 18th September 2025, the LiquiDx consortium gathered at the Biobanco del Sistema Sanitario Público de Andalucía (BBSSPA) facilities in Granada for the final face-to-face meeting of the project. The sessions, which were also transmitted by videoconference, served to review the progress made to develop an RNA-based liquid biopsy tool for the early detection of five major cancers: lung, colon, breast, prostate, and pancreas. Lessons learned were shared about the quality requirements of plasma samples and how to mitigate batch effects in biomarker discovery. The meeting concluded with discussions on how to prepare the final technical report and a guided tour of BBSSPA’s facilities.

The LiquiDx project made a significant step forward in the innovation of cfRNA-based liquid biopsies, combining next-generation sequencing, bioinformatics, and precision medicine solutions to create a cutting-edge diagnostic platform for use in clinical settings. These developments highlight the consortium’s commitment to advancing early cancer detection and accelerating the translation of new technologies into accessible clinical tools to improve patient outcomes. The main outcomes of LiquiDx are also planned to be shared with the scientific community in a scientific publication.

Flomics Biotech, Leitat and BBSSPA acknowledge the financial support received for the LiquiDx project, associated with the action with action file number CPP2021-008897, which was financed by MCIN/AEI/10.13039/501100011033 and by the European Union “NextGenerationEU/PRTR”, through the 2021 call for public-private collaboration projects of the Agencia Estatal de Investigación.

Flomics
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.